CLINICAL PIPELINE

TRACT Therapeutics has successfully completed the Phase I Kidney Trial, utilizing the patient’s own regulatory T cells after a kidney transplant.​

There were no serious adverse events attributable to the treatment, and additional data analyzed showed signals toward efficacy. A manuscript entitled, “A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T Cells in Living Donor kidney Transplants” was published in SCIENTIFIC REPORTS in 2018.

PIPELINE

Phase 1

Indication

Kidney Transplant

Crohn's Disease

Preclinical

Phase 2

Phase 3